Is crizotinib a MET inhibitor?
Based on initial data from this study, crizotinib as a MET inhibitor received breakthrough therapy designation from the United States Food and Drug Administration (US FDA) in 2018 for previously treated metastatic NSCLC in patients with MET exon 14 skipping.
What is a MET mutation?
A gene that makes a protein that is involved in sending signals within cells and in cell growth and survival. Mutated (changed) forms of the MET gene may cause abnormal cells to grow and spread in the body.
WHAT IS MET amplification?
MET Amplification is a predictive biomarker for use of capmatinib, crizotinib, afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib in patients. Of the therapies with MET Amplification as a predictive biomarker, 7 have NCCN guidelines in at least one clinical setting.
What is MET exon 14 skipping mutation?
MET exon 14 skipping mutation (MET∆ex14) is present about 3% of non-small cell lung cancers (NSCLCs). NSCLC patients with MET∆ex14 are characterized by an average age of over 70 years at diagnosis, a smoking history and a higher frequency in pleomorphic carcinoma and adenosquamous cell carcinoma than in adenocarcinoma.
Is crizotinib cytotoxic?
In this study, crizotinib induced dose-dependent inhibition of growth of multiple breast cancer cell lines in vitro. In addition, acute exposure to crizotinib resulted in cytotoxic activity in the different cell lines investigated.
What type of gene is MET?
GeneCards Summary for MET Gene MET (MET Proto-Oncogene, Receptor Tyrosine Kinase) is a Protein Coding gene. Diseases associated with MET include Renal Cell Carcinoma, Papillary, 1 and Deafness, Autosomal Recessive 97. Among its related pathways are Semaphorin interactions and Phospholipase-C Pathway.
How do you determine MET amplification?
Detection of MET amplification can be performed by several techniques such as Southern blot, polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH).
WHAT IS MET amplification NSCLC?
MET amplification is a potential resistance pattern of EGFR-TKIs in NSCLC, accounting for 50–60% of the first- and second-generation EGFR-TKIs acquired resistance,31,32,84 accounting for 15–19% of the third-generation EGFR-TKIs acquired resistance.
How do you use crizotinib?
Crizotinib is usually taken twice per day, with or without food. Swallow the capsule whole and do not crush, chew, break, or open it. You may need frequent medical tests to be sure this medicine is not causing harmful effects. Your cancer treatments may be delayed based on the results.
How long is crizotinib effective?
According to the findings, published in NEJM on December 4, 2014, patients treated with crizotinib had a median progression-free survival of 10.9 months, compared with 7.0 months for patients receiving chemotherapy with pemetrexed plus cisplatin or carboplatin.
Is crizotinib effective in advanced NSCLC with met exon 14 alterations?
The study team assessed antitumour activity and safety of crizotinib in 69 patients with advanced NSCLCs harbouring MET exon 14 alterations. Objective response rate was 32% (95% confidence interval (CI), 21–45) among 65 patients evaluable for response.
How does crizotinib affect MET kinase activity?
This leads to decreased turnover of MET and increased MET signaling that drives oncogenesis; however, additional mechanisms contributing to altered MET kinase activity cannot be excluded. Crizotinib is a multi-tyrosine kinase inhibitor that is approved for the treatment of ALK – or ROS1 -rearranged advanced NSCLCs.
Does crizotinib work for met-amplified non-small cell lung cancer?
In conclusion, patients with MET -amplified NSCLC responded to crizotinib treatment, with the highest ORRs observed among patients with high-level amplification suggesting MET amplification as a novel actionable NSCLC subtype.
What is the response-evaluable population for crizotinib?
Patients who received ≥1 dose of crizotinib were included in the safety population and analyses of PFS and OS. The response-evaluable population was defined as all patients in the safety population who had an adequate baseline and ≥1 post-baseline disease assessment (≥6 weeks from the first dose), or who withdrew from the study, progressed or died.